Latest:
Dr Patel on the FDA Approval of Durvalumab Plus Chemotherapy for NSCLC
Sandip P. Patel, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sandra Demaria, MD
Latest:
Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens
Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.
Sandra Hanner
Latest:
IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer
Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.
Sandra Kelly, RN, MS, NP, Nurse Practitioner Brigham & Women’s Hospital
Latest:
Immunotherapy: Personalized Treatment for Advanced Prostate Cancer
In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Sandra P. D’Angelo, MD
Latest:
Novel Molecular Targets for Drug Development in Non-GIST Sarcomas
The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.
Sandy Truong, Harvard Medical School studentÂ
Latest:
Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology Clinic
Ann Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.
Sangeetha Palakurthi, PhD
Latest:
Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC
Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).
Sanjaya K. Satapathy, MD
Latest:
Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC
Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.
Sanjiv S. Agarwala, MD
Latest:
Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade
Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.